CureVac N.V.
Frankfurt Stock Exchange 5CV.F
CureVac N.V. Price to Earnings Ratio (P/E) on January 14, 2025: -3.28
-
CureVac N.V. 52-week high Price to Earnings Ratio (P/E) is -1.98 on April 26, 2024, which is 39.74% above the current Price to Earnings Ratio (P/E).
-
CureVac N.V. 52-week low Price to Earnings Ratio (P/E) is -4.30 on June 06, 2024, which is -31.23% below the current Price to Earnings Ratio (P/E).
-
CureVac N.V. average Price to Earnings Ratio (P/E) for the last 52 weeks is -2.73.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Dr. Alexander Zehnder M.B.A., M.D. |
| IPO Date | Aug. 14, 2020 |
| Location | Germany |
| Headquarters | Friedrich-Miescher-Strasse 15 |
| Employees | 999 |
| Sector | Health Care |
| Industries | |
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Past 5 years
USD 116.36
StockViz Staff
January 15, 2025
Any question? Send us an email